Literature DB >> 1579084

Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

C Peeters1, A M Tenbergen-Meekes, J Poolmann, B Zegers, G Rijkers.   

Abstract

We have prepared polysaccharide-protein conjugates consisting of type 4 pneumococcal capsular polysaccharide (PS4) coupled to tetanus toxoid. The PS4 preparation used contained 2.5% pneumococcal cell wall polysaccharide (CPs). During the conjugation process, in addition to PS4-protein conjugates, CPs-protein conjugates were also formed. After immunization with PS4-protein conjugates, CPs-protein conjugates that are present as a contaminant induce IgG anti-CPs antibodies in mice. Pneumococcal oligosaccharides, prepared by periodate oxidation of PS4, did not contain detectable amounts of CPs; hence, oligosaccharide-protein conjugates did not induce anti-CPs antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579084     DOI: 10.1007/bf00193394

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  29 in total

1.  Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine.

Authors:  A J Carlson; W L Davidson; A A McLean; P P Vella; R E Weibel; A F Woodhour; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1979-09

2.  Type 6 and 19 pneumococcal polysaccharides coupled to erythrocytes elicit pneumococcal cell wall-specific primary IgM responses and capsular polysaccharide-specific secondary IgG responses.

Authors:  G N Milligan; R L Fairchild; K E Sterner; H Braley-Mullen
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

3.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.

Authors:  C C Peeters; A M Tenbergen-Meekes; D E Evenberg; J T Poolman; B J Zegers; G T Rijkers
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

5.  Production and characterization of monoclonal antibodies specific for types 6 and 19 pneumococcal capsular polysaccharides.

Authors:  G N Milligan; H Braley-Mullen
Journal:  Mol Immunol       Date:  1989-09       Impact factor: 4.407

6.  C-polysaccharide in a pneumococcal vaccine.

Authors:  U B Sørensen; J Henrichsen
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-12

7.  Anti-C-carbohydrate antibodies after pneumococcal vaccination.

Authors:  F K Pedersen; J Henrichsen; U S Sørensen; J L Nielsen
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1982-12

8.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types.

Authors:  S C Szu; S Clarke; J B Robbins
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Pneumococcal antibodies of different immunoglobulin subclasses in normal and IgG subclass deficient individuals of various ages.

Authors:  B Rynnel-Dagöö; A Freijd; L Hammarström; V Oxelius; M A Persson; C I Smith
Journal:  Acta Otolaryngol       Date:  1986 Jan-Feb       Impact factor: 1.494

View more
  1 in total

Review 1.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.